[
  {
    "question": "scenario of IBM 1 about rx:",
    "option_a": "Supportive care",
    "option_b": "Prednisone",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Inclusion Body Myositis (IBM) is an inflammatory myopathy that typically manifests in older individuals, characterized by progressive muscle weakness predominantly affecting the quadriceps and the forearm flexors. Unlike polymyositis or dermatomyositis, IBM is notably resistant to immunosuppressive therapy. IBM involves a combination of inflammatory and degenerative processes within the muscle tissue, including endomysial inflammation, rimmed vacuoles, and abnormal protein aggregates. Current evidence suggests that both autoimmune mechanisms and degenerative muscle fiber changes contribute to disease progression. Clinically, IBM often presents with a slowly progressive weakness that affects the proximal and distal muscles. Dysphagia can also occur. The disease has a predilection for older adults, and a poor response to corticosteroids or other immunosuppressants is a distinguishing feature. Diagnosis is based on clinical examination, laboratory markers (such as mild to moderate CK elevation), and confirmatory muscle biopsy demonstrating characteristic features like rimmed vacuoles and endomysial inflammation. Differential diagnoses include polymyositis and dermatomyositis, but these usually respond to corticosteroids. Current treatment guidelines emphasize supportive care since immunosuppressive therapies like prednisone have shown minimal benefit in IBM. Supportive management includes physical therapy, exercise programs, and assistive devices to maintain function. In terms of pregnancy and lactation, immunosuppressant use would be carefully weighed; however, in IBM, these agents are generally not beneficial regardless of patient status. Option A (Supportive care) is correct as IBM does not typically respond to corticosteroids like prednisone, making supportive care the mainstay of treatment. Option B (Prednisone) is not recommended given its lack of efficacy in IBM. Options C and D were not provided. 1. IBM is the most common idiopathic inflammatory myopathy in patients over 50 years. 2. It is characterized by selective involvement of the quadriceps and forearm flexors. 3. Muscle biopsy is key in differentiating IBM from other inflammatory myopathies. Recent research reaffirms that corticosteroids and other immunosuppressants do not alter the course of IBM, and current consensus guidelines recommend a focus on supportive measures and physical therapy to maintain patient mobility and quality of life.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "a middle age lady who presented with problem with attention and tremor and progressive ataxia what is the most likely diagnosis (? Wilson) what are you going to do next?",
    "option_a": "paraneoplastic",
    "option_b": "Alzheimer type 2 (or 3)",
    "option_c": "24-hour urine copper",
    "option_d": "was not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Movement Disorders",
    "explanation": "Wilson disease is a genetic disorder of copper metabolism caused by mutations in the ATP7B gene, resulting in copper accumulation predominantly in the liver and brain. Although typically presenting in younger individuals, clinical suspicion can arise in middle-aged patients with neurological manifestations. The ATP7B gene mutation leads to impaired biliary copper excretion and reduced incorporation of copper into ceruloplasmin. This causes toxic copper accumulation in tissues, resulting in hepatic injury and neuropsychiatric symptoms including tremor, ataxia, and cognitive changes. In Wilson disease, patients may present with a range of symptoms from hepatic dysfunction to neurological abnormalities such as movement disorders (tremor, ataxia) and psychiatric disturbances. The presence of Kayser-Fleischer rings on ophthalmologic exam is another key clinical clue. The diagnostic workup involves initial screening with serum ceruloplasmin levels (typically low in Wilson disease) followed by a 24-hour urine copper measurement, which is commonly elevated due to increased copper excretion. Liver biopsy and genetic testing may also be used for confirmation. Differential diagnoses include other causes of tremor and ataxia like paraneoplastic syndromes or other metabolic disorders. First-line management for Wilson disease involves chelation therapy using agents such as penicillamine or trientine to promote copper excretion. Zinc is also used as maintenance therapy by decreasing copper absorption. In pregnancy and lactation, careful management is essential: penicillamine may be used with caution while monitoring for adverse effects, and zinc is considered safer, but treatment should be individualized. Option A (paraneoplastic) is incorrect as it does not fit the profile of copper accumulation disorders. Option B (Alzheimer type 2/3) is unrelated to copper metabolism and does not present with the described features. Option C (24-hour urine copper) is the appropriate investigative step for suspected Wilson disease. Option D was not provided. 1. Wilson disease should be suspected in patients with combined hepatic and neurological symptoms, even if the age of presentation is atypical. 2. Kayser-Fleischer rings are a significant clinical sign and should prompt further copper studies. 3. Early diagnosis and treatment are critical to prevent irreversible neurological damage. Recent guidelines continue to endorse a combination of serum ceruloplasmin and 24-hour urine copper testing as primary diagnostic modalities. Advances in genetic testing are increasingly used to support the biochemical findings, and current clinical trials are exploring improved chelation protocols and treatment regimens.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario about a patient with parkinsonism, Urinary symptoms? Falls What would you find on MRI??",
    "option_a": "HUMMING BIRD",
    "option_b": "HOT CROSS BUN",
    "option_c": "PANDA face",
    "option_d": "TIGER eyes",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder that features a combination of parkinsonism, autonomic dysfunction (such as urinary incontinence), and sometimes cerebellar signs. The 'hot cross bun' sign on MRI is a characteristic neuroradiological feature associated with MSA, especially the cerebellar subtype. MSA involves widespread neurodegeneration affecting the striatonigral and olivopontocerebellar systems. The degeneration of pontine structures and transverse pontocerebellar fibers gives rise to the distinctive cruciform hyperintensity seen on T2-weighted MRI sequences, known as the hot cross bun sign. Patients with MSA often present with a combination of parkinsonian features (such as rigidity and bradykinesia), early autonomic failure (urinary incontinence, orthostatic hypotension), and frequent falls. These features help distinguish MSA from Parkinson\u2019s disease, in which autonomic symptoms and falls are usually less prominent in the early stages. The diagnosis of MSA is clinical and supported by neuroimaging. MRI is used to identify characteristic findings such as the hot cross bun sign, which helps differentiate it from other parkinsonian disorders. Differential diagnoses include Parkinson\u2019s disease (which typically shows preserved pontine structure), Progressive Supranuclear Palsy (with the hummingbird sign on midbrain imaging), and other atypical parkinsonian syndromes. Management of MSA is primarily symptomatic. Levodopa may be trialed for parkinsonian symptoms, though its efficacy is often limited. Treatment also focuses on managing autonomic dysfunction, such as using fludrocortisone or midodrine for orthostatic hypotension and appropriate non-pharmacological measures for urinary incontinence. No disease-modifying therapies are available. Given that MSA primarily affects older adults, pregnancy and lactation considerations are generally not applicable. Option A (Humming Bird) refers to a midbrain sign seen in Progressive Supranuclear Palsy (PSP), not MSA. Option B (Hot Cross Bun) is correct as it describes the classic pontine MRI appearance in MSA. Option C (Panda Face) is more commonly associated with Wilson disease (the \u2018face of the giant panda\u2019 sign), and Option D (Tiger Eyes) is not a recognized neuroradiological sign in this context. 1. The hot cross bun sign is highly suggestive of MSA and should prompt evaluation of both parkinsonian and autonomic symptoms. 2. Early prominent autonomic dysfunction in a parkinsonian patient should raise suspicion for MSA over idiopathic Parkinson\u2019s disease. 3. MRI plays a crucial role in differentiating atypical parkinsonian syndromes. Recent studies have reinforced the utility of advanced MRI techniques in enhancing diagnostic accuracy for MSA. Current clinical guidelines emphasize the importance of a multidisciplinary approach to manage the complex symptoms of MSA, although no neuroprotective treatments have yet been validated.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of cervical dystonia rx:",
    "option_a": "Botox",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Cervical dystonia (spasmodic torticollis) is a focal dystonia characterized by involuntary, sustained muscle contractions of the neck that lead to abnormal posturing and often pain. The disorder usually involves a dysfunction in motor control with aberrant neural signaling causing specific muscles to contract. The underlying mechanism is thought to involve dysfunctional basal ganglia circuits and impaired sensorimotor integration. Neurotransmitter imbalances, particularly of GABA and dopamine, contribute to abnormal inhibitory control over motor pathways. Genetic factors may be implicated in some cases, and abnormal cortical plasticity can also play a role. Patients typically present with abnormal head posturing, neck pain, and sometimes head tremor. Many patients report a 'sensory trick' (geste antagoniste) that temporarily alleviates the dystonia. The diagnosis is clinical, based on history and physical exam, although ancillary testing (like EMG) can assist in treatment planning. Diagnosis is usually clinical. Electromyography (EMG) may be used to localize overactive muscles and guide botulinum toxin injections. Differential diagnoses include tardive dyskinesia, other movement disorders, and even musculoskeletal issues which can be differentiated by the characteristic involuntary and patterned nature of the contractions. Current guidelines recommend botulinum toxin injections (e.g., Botox) as the first\u2010line treatment for cervical dystonia. The injections are usually targeted to overactive muscles using clinical and sometimes EMG guidance. Oral medications (such as anticholinergics or muscle relaxants) may be considered as adjuncts or second\u2010line therapy. In pregnant or lactating women, botulinum toxin should be used with caution; if benefits outweigh potential risks, lower doses and careful monitoring are advised. Option A (Botox) is correct because it is the standard first-line treatment for cervical dystonia. The absence of other options does not detract from the fact that botulinum toxin injections have been shown to significantly reduce symptoms and improve quality of life. 1. Sensory tricks are a hallmark of dystonia and can help in making a clinical diagnosis. 2. Botulinum toxin injections improve symptoms in a majority of patients with cervical dystonia. 3. Careful dose titration is important, especially in populations like pregnant or lactating women where risks must be balanced against benefits. Recent studies and updated guidelines continue to support the use of botulinum toxin injections as the first-line management option, with improvements in injection techniques and individualized dosing strategies contributing to enhanced patient outcomes.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "a young female patient present to clinic with head tremor and neck pain, on exam she has latricollis and report improvement with her symptoms when she face the wall what is the most accurate statement:",
    "option_a": "she has good response for sensory trick",
    "option_b": "treatment with Botox is contraindicated",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "A sensory trick (geste antagoniste) is a distinctive feature seen in dystonia where a specific maneuver or touch can transiently alleviate abnormal posturing or tremor. This phenomenon is particularly common in cervical dystonia. Although not completely understood, it is thought that the sensory input modifies abnormal proprioceptive feedback and disrupts the abnormal motor signaling caused by basal ganglia dysfunction. The temporary normalization of motor output leads to symptom improvement. A young female presenting with head tremor, neck pain, and improvement of symptoms when facing the wall (a sensory trick) is highly suggestive of cervical dystonia. This maneuver differentiates dystonia from other tremor disorders where such a trick is not typically observed. The diagnosis is primarily clinical. While EMG can help in delineating the involved muscles, the sensory trick is a strong clinical indicator of dystonia. Differential diagnoses include essential tremor and psychogenic movement disorders, but these typically lack a reproducible sensory trick. The first-line treatment for cervical dystonia remains botulinum toxin injections. Adjunct therapies include physical therapy and oral medications. In special populations such as pregnant or lactating women, non-pharmacologic management and careful evaluation of risks versus benefits for botulinum toxin use are essential. Option A is correct because a good response to a sensory trick (improvement when facing the wall) is a classic clinical feature of cervical dystonia. Option B, stating that treatment with Botox is contraindicated, is incorrect as Botox is the standard treatment unless specific contraindications exist. 1. Sensory tricks are almost pathognomonic for dystonia and help differentiate it from other movement disorders. 2. Even simple maneuvers observed during the physical exam can provide strong diagnostic clues. 3. Botulinum toxin remains the cornerstone of treatment for cervical dystonia. Recent literature continues to validate the diagnostic importance of the sensory trick in dystonia and supports botulinum toxin injections as the most effective treatment modality based on multiple controlled trials and meta-analyses.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Pt is impulsive and drug seeker with scenario of RLS what is the Rx:",
    "option_a": "Clonazepam",
    "option_b": "Gabapentin",
    "option_c": "Pramipexole",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Restless Legs Syndrome (RLS) is a sensorimotor neurological disorder characterized by an uncontrollable urge to move the legs, typically accompanied by uncomfortable sensations, which worsen during periods of inactivity and at night. RLS is believed to result from dysfunction in central dopaminergic pathways and abnormalities in iron metabolism within the central nervous system. In patients prone to impulsive behavior or substance abuse, the use of dopamine agonists (the standard first-line therapy) can exacerbate impulsivity and lead to impulse control disorders. The patient\u2019s description, combined with the behavioral profile (impulsive and drug-seeking), makes the choice of therapeutic agent particularly important. While dopamine agonists like pramipexole are typically first-line for RLS, they carry the risk of promoting impulse control disorders in vulnerable individuals. RLS is a clinical diagnosis made on the basis of the patient\u2019s history\u2014criteria include an urge to move the legs, worsening at rest, and relief with movement\u2014and the exclusion of other conditions such as peripheral neuropathy, akathisia, and nocturnal leg cramps. Although dopamine agonists (e.g., pramipexole) are generally considered first-line treatment for RLS, in patients with a predisposition to impulsivity or substance misuse, non-dopaminergic options such as gabapentin (an alpha-2-delta ligand) are preferred. Gabapentin is effective in alleviating RLS symptoms along with associated dysesthesias and sleep disturbances. In pregnancy and lactation, caution is needed with all pharmacologic treatments; decisions must balance maternal benefit with fetal/neonatal risk, and non-pharmacologic measures are often preferred when possible. Option B (Gabapentin) is correct in this scenario because it minimizes the risk of aggravating impulse control issues that can be seen with dopamine agonists like pramipexole. Option A (Clonazepam) is not a first-line agent for RLS and is generally used as an adjunct; Option C (Pramipexole) though generally first-line, is less appropriate here due to the patient\u2019s impulsive behavior. 1. In RLS, always consider the patient's behavioral profile before initiating dopamine agonists. 2. Gabapentin is a valuable alternative in patients with a history of impulse control disorders. 3. A careful assessment of iron status may also be warranted as part of the initial workup. Recent guideline updates endorse individualized treatment plans for RLS. In patients at risk for impulse control disorders, alpha-2-delta ligands like gabapentin are being increasingly recommended over dopamine agonists, and ongoing studies continue to refine these recommendations based on long-term outcomes and side effect profiles.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of Orthostatic tremor what will do:",
    "option_a": "NCS and EMG",
    "option_b": "Other choices?",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Orthostatic tremor is a rare movement disorder characterized by a rapid, rhythmic tremor in the legs when standing, leading to a sensation of unsteadiness that typically improves upon sitting or walking. The disorder is thought to arise from abnormal oscillatory activity within central nervous system networks that control posture and balance. EMG studies reveal high-frequency rhythmic bursts (usually 13-18 Hz) in the leg muscles during standing. Patients report a feeling of instability and may even be unable to stand for long durations. The tremor is often not visibly apparent and is best detected with electromyography (EMG). The sudden alleviation of symptoms with movement is a key clinical hallmark. The gold standard for diagnosing orthostatic tremor is a surface EMG performed while the patient is standing, which displays the characteristic high-frequency burst pattern. Nerve conduction studies (NCS) may be performed concurrently to rule out other peripheral neuropathies, though they are not diagnostic of OT per se. Differential diagnoses include essential tremor and other postural tremors, which lack the distinct high-frequency component seen in OT. Treatment options for orthostatic tremor are limited and mainly symptomatic. Medications such as clonazepam, gabapentin, or primidone have been used with variable success. Non-pharmacologic strategies including physical therapy may help improve functional mobility. In special populations like pregnant or lactating women, non-pharmacologic approaches are preferred, and if pharmacotherapy is needed, agents with the safest profiles (e.g., low-dose benzodiazepines with careful monitoring) should be considered. Option A (NCS and EMG) is correct because the definitive diagnosis of orthostatic tremor relies on electrophysiological studies\u2014particularly EMG\u2014to capture the high-frequency tremor pattern. Other options are either not specified or do not address the key diagnostic test in this scenario. 1. Orthostatic tremor is best confirmed by EMG showing a high-frequency (13-18 Hz) tremor. 2. Symptoms improve markedly on sitting or walking, which is a diagnostic clue. 3. Despite its rarity, proper electrophysiological evaluation is essential in patients presenting with unexplained unsteadiness on standing. Contemporary research reinforces the use of surface EMG as the diagnostic gold standard for orthostatic tremor. Treatment studies continue to explore optimal pharmacologic and rehabilitative strategies, though evidence remains limited due to the rarity of the disorder.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of orthostatic tremor not responding to clonazepam:",
    "option_a": "Levodopa",
    "option_b": "propranolol",
    "option_c": "gabapentin",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Movement Disorders",
    "explanation": "Orthostatic tremor is a rare movement disorder that manifests as a high\u2010frequency (typically 13\u201318 Hz) tremor in the legs when the patient is standing. Patients experience unsteadiness on standing that quickly resolves when sitting or walking. The underlying mechanism remains somewhat elusive, but research indicates an abnormal central oscillatory network, likely involving the cerebellum, brainstem, or both. Electromyographic (EMG) studies characteristically reveal high-frequency rhythmic bursts during standing. Clinically, patients present with rapid leg tremors and subjective feelings of instability when upright. This distinctive postural dependency (present on standing, absent while sitting or walking) helps differentiate it from other tremor disorders. Diagnosis is primarily clinical, supported by EMG confirmation. Differential diagnoses include essential tremor (which is lower in frequency and typically present during maintained posture), orthostatic myoclonus, and Parkinson disease (characterized by rest tremor). Careful history and examination, along with targeted EMG studies, help in distinguishing these conditions. First\u2010line treatment is usually clonazepam due to its GABAergic mechanism. For patients who do not respond to clonazepam, gabapentin is considered a second\u2010line option. In managing women who are pregnant or lactating, caution is advised: clonazepam is a benzodiazepine with potential teratogenic effects and neonatal sedation, while gabapentin is generally categorized as pregnancy category C and should be used only when the benefits outweigh the risks. Option A (Levodopa) is typically used for tremors related to Parkinson\u2019s disease and does not address the high\u2010frequency nature of orthostatic tremor. Option B (Propranolol) is effective in essential tremor but not in orthostatic tremor. Option C (Gabapentin) is the appropriate alternative when clonazepam is ineffective. Option D is not provided. 1. Orthostatic tremor is best suspected in patients who report shaky legs only upon standing, with resolution on sitting. 2. Gabapentin represents an effective second\u2010line treatment for those patients not responding to clonazepam. Recent literature and case series continue to support the use of gabapentin in clonazepam\u2010refractory orthostatic tremor. Advances in EMG techniques and neuroimaging further our understanding of the disorder\u2019s pathogenesis, which may lead to more targeted treatments in the future.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of rubral tremor in MS pt. Rx:",
    "option_a": "Levodopa",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Orthostatic tremor is a rare movement disorder that manifests as a high\u2010frequency (typically 13\u201318 Hz) tremor in the legs when the patient is standing. Patients experience unsteadiness on standing that quickly resolves when sitting or walking. The underlying mechanism remains somewhat elusive, but research indicates an abnormal central oscillatory network, likely involving the cerebellum, brainstem, or both. Electromyographic (EMG) studies characteristically reveal high-frequency rhythmic bursts during standing. Clinically, patients present with rapid leg tremors and subjective feelings of instability when upright. This distinctive postural dependency (present on standing, absent while sitting or walking) helps differentiate it from other tremor disorders. Diagnosis is primarily clinical, supported by EMG confirmation. Differential diagnoses include essential tremor (which is lower in frequency and typically present during maintained posture), orthostatic myoclonus, and Parkinson disease (characterized by rest tremor). Careful history and examination, along with targeted EMG studies, help in distinguishing these conditions. First\u2010line treatment is usually clonazepam due to its GABAergic mechanism. For patients who do not respond to clonazepam, gabapentin is considered a second\u2010line option. In managing women who are pregnant or lactating, caution is advised: clonazepam is a benzodiazepine with potential teratogenic effects and neonatal sedation, while gabapentin is generally categorized as pregnancy category C and should be used only when the benefits outweigh the risks. Option A (Levodopa) is typically used for tremors related to Parkinson\u2019s disease and does not address the high\u2010frequency nature of orthostatic tremor. Option B (Propranolol) is effective in essential tremor but not in orthostatic tremor. Option C (Gabapentin) is the appropriate alternative when clonazepam is ineffective. Option D is not provided. 1. Orthostatic tremor is best suspected in patients who report shaky legs only upon standing, with resolution on sitting. 2. Gabapentin represents an effective second\u2010line treatment for those patients not responding to clonazepam. Recent literature and case series continue to support the use of gabapentin in clonazepam\u2010refractory orthostatic tremor. Advances in EMG techniques and neuroimaging further our understanding of the disorder\u2019s pathogenesis, which may lead to more targeted treatments in the future.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "17-year-old boy who developed tic since the age of 11, it was multiple tics verbal and motor What is the diagnosis",
    "option_a": "Gills Tourette",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Tourette syndrome is a neuropsychiatric disorder characterized by the presence of multiple motor tics and at least one vocal tic persisting for more than one year, with onset before the age of 18. In this case, a 17-year-old boy with tics starting at age 11, displaying both verbal and motor tics, meets the clinical criteria for Tourette syndrome. The pathophysiology of Tourette syndrome involves dysfunction in the cortico-striato-thalamo-cortical circuits with altered dopamine transmission. Studies indicate a genetic predisposition, and environmental factors, such as perinatal stress or infections, may also contribute to the development of the disorder. Clinically, Tourette syndrome often presents in childhood/adolescence with a waxing and waning course. Many patients may have associated comorbidities like attention-deficit/hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), and learning disabilities. Recognition of these comorbidities is essential for comprehensive management. Diagnosis is primarily clinical. The essential criteria include onset before 18, a duration of more than one year of both motor and one or more vocal tics, and absence of an alternative medical condition or substance-induced cause. Differential diagnoses include transient tic disorder (tics lasting <1 year) and chronic motor or vocal tic disorder (only one type of tic present). Management involves a combination of behavioral, educational, and pharmacologic interventions. The first-line non-pharmacologic treatment is behavioral therapy, specifically Comprehensive Behavioral Intervention for Tics (CBIT). Pharmacologic treatments include antipsychotic medications (e.g., risperidone, aripiprazole) and alpha-2 adrenergic agonists (e.g., clonidine). In pregnant or lactating patients, non-pharmacologic therapies are preferred, and if medications are necessary, those with a better safety profile should be chosen based on up-to-date guidelines to minimize risks to the fetus or infant. Option A, 'Gills Tourette', is intended to refer to Gilles de la Tourette syndrome. Even though the wording is slightly off, it correctly reflects the diagnosis given the clinical presentation. With the other options not provided, Option A stands as the best and correct answer. Tics in Tourette syndrome can often be briefly suppressed voluntarily, and their severity can be influenced by stress and attention. It is essential to assess for and manage any associated conditions such as ADHD or OCD. Overall, a multidisciplinary approach usually offers the best outcome. Recent research continues to validate the efficacy of behavioral interventions like CBIT and supports cautious use of pharmacologic agents, particularly in populations such as pregnant or lactating patients. Ongoing studies into the underlying neurobiology may eventually lead to new therapeutic targets, including neuromodulatory techniques for refractory cases.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario about 50 y/o female with recent intention tremor and memory problem with MRI finding of cerebellar peduncle changes (fragile x but nor that clear scenario) dx:",
    "option_a": "Fragile x (it was mentioned as X permutation)",
    "option_b": "paraneoplastic",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Fragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder seen in carriers of the FMR1 premutation. It typically presents in older adults with symptoms such as intention tremor, ataxia, and cognitive deficits. Characteristic MRI findings include white matter changes, especially hyperintensities in the middle cerebellar peduncles (the 'MCP sign'). Although FXTAS is more common in males, affected females can exhibit milder symptoms due to X-inactivation and mosaicism. FXTAS results from an RNA toxic gain-of-function effect due to a CGG repeat expansion in the FMR1 gene (premutation range). Elevated levels of the aberrant FMR1 mRNA lead to intranuclear inclusions and white matter changes, particularly in the cerebellum and brainstem, resulting in tremor, ataxia, and cognitive impairment. In this case, a 50-year-old female presenting with intentional tremor and memory problems, along with MRI findings demonstrating cerebellar peduncle changes, is highly suggestive of FXTAS. The clinical picture aligns with FXTAS despite its higher prevalence in males, as females can also develop the syndrome, typically with a less severe presentation. The key steps include: 1) a detailed clinical history and neurological examination to document tremor, ataxia, and cognitive changes; 2) neuroimaging, particularly MRI, to identify the 'MCP sign' and other white matter abnormalities; 3) molecular genetic testing for an FMR1 CGG repeat expansion in the premutation range, which confirms the diagnosis. Differential diagnoses to consider include paraneoplastic cerebellar degeneration, multiple system atrophy (cerebellar variant), and other cerebellar ataxias. There is currently no cure for FXTAS; management is supportive and aimed at symptom relief. Pharmacologic options for tremor include beta-blockers and primidone, though caution must be used especially in women of child-bearing potential, pregnant, or lactating patients, due to potential medication risks. Non-pharmacologic interventions such as physical, occupational, and speech therapies are important. Cognitive support and monitoring are also beneficial. In pregnant or lactating patients, treatment choices should be carefully balanced with teratogenic risks and safety profiles. Option A (Fragile X/FXTAS) directly corresponds to a clinical syndrome that explains the patient's age, symptomatology (intention tremor and memory issues), and specific MRI findings (cerebellar peduncle changes), making it the most logical choice. Option B (paraneoplastic) is less consistent with the characteristic MCP MRI findings and the classic constellation of findings in FXTAS, even though paraneoplastic cerebellar degeneration can cause ataxia; its imaging and clinical patterns differ. \u2022 The presence of the MCP sign on MRI is a key indicator of FXTAS. \u2022 Although FXTAS is more common in males, female carriers can also be affected, often with milder clinical manifestations due to X-inactivation. \u2022 Always consider genetic testing for the FMR1 premutation when FXTAS is suspected. Recent clinical guidelines and research underscore the importance of genetic confirmation for FXTAS and support a multidisciplinary approach to management focusing on symptomatic relief and supportive care. There is a continuing need for careful medication selection in special populations such as pregnant or lactating women, with close consultation regarding the safety profiles of agents like beta-blockers and primidone.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Sydenham chorea what to do:",
    "option_a": "ASO titer",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Sydenham chorea is a neuropsychiatric manifestation typically seen in children as a major criterion of acute rheumatic fever. It is thought to result from an autoimmune reaction triggered by a group A Streptococcus infection. Laboratory evidence of a preceding strep infection, such as an elevated antistreptolysin O (ASO) titer, supports the diagnosis. After an infection with group A Streptococcus, molecular mimicry can lead to the production of antibodies that cross-react with basal ganglia neurons. This autoimmune attack results in the characteristic involuntary, purposeless movements of Sydenham chorea. Children, particularly between the ages of 5 and 15, may present with rapid, irregular, and non-rhythmic movements, emotional lability, and hypotonia. The demonstration of an elevated ASO titer correlates with a recent streptococcal infection, linking the clinical picture with its underlying etiology. The diagnosis is largely clinical based on the presence of choreiform movements and a history suggestive of a recent strep infection. Supporting diagnostics include an ASO titer and anti-DNase B antibodies. Differentials include other causes of chorea such as Wilson's disease, Huntington's disease, and drug-induced chorea, which are differentiated by age, clinical history, and appropriate laboratory/imaging studies. Management involves supportive care with symptomatic treatment (e.g., benzodiazepines for severe chorea) and, importantly, antibiotic prophylaxis (usually with penicillin) to prevent recurrence of group A Streptococcal infections. In pregnancy and lactation, penicillin remains the first-line antibiotic for prophylaxis, given its safety profile. Option A (ASO titer) is correct because it is a widely used test to confirm a recent group A streptococcal infection, which is central to the diagnosis of Sydenham chorea. The absence of other options does not detract from the appropriateness of obtaining an ASO titer in this clinical scenario. 1) Sydenham chorea is self-limiting but may persist for weeks to months. 2) An elevated ASO titer is an important laboratory clue confirming a recent streptococcal infection. 3) Cardiac evaluation is essential as rheumatic fever can also affect the heart valves. Current guidelines support the use of ASO titers along with clinical criteria for diagnosing rheumatic fever. Ongoing research continues to explore immunomodulatory treatments, although the mainstay remains supportive care and antibiotic prophylaxis.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "RLS most commonly with:",
    "option_a": "Pregnancy is a risk factor",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Restless Legs Syndrome (RLS) is a sensorimotor disorder characterized by an uncomfortable urge to move the legs, typically worsening at rest and in the evening. Its prevalence is increased in certain populations, including pregnant women. RLS is believed to involve dysfunction in dopaminergic pathways along with iron deficiency in the central nervous system. During pregnancy, especially in the third trimester, increased iron requirements and hormonal changes may exacerbate or unmask RLS symptoms. Patients with RLS experience an urge to move their legs accompanied by unpleasant sensations, usually improving with activity. Pregnancy is a well-recognized risk factor, likely due to altered iron metabolism, that can precipitate or worsen RLS symptoms. The diagnosis of RLS is primarily clinical, based on patient history and symptomatology. Differential diagnoses include nocturnal leg cramps, peripheral neuropathy, and akathisia. Iron studies (especially serum ferritin) are important to rule out iron deficiency as a contributing cause. First-line management typically includes non-pharmacologic approaches like improved sleep hygiene, moderate exercise, and leg stretching. Iron supplementation is recommended if deficiency is identified. Pharmacologic therapy (e.g., low-dose dopamine agonists) may be considered for moderate-to-severe cases. In pregnant or lactating women, treatment is conservative; non-pharmacologic measures and iron repletion are prioritized, given the safety profiles required during these periods. Option A (Pregnancy is a risk factor) is correct as numerous studies have shown a higher incidence of RLS in pregnant women, particularly in the later stages of pregnancy. The hormonal and metabolic changes during pregnancy significantly contribute to this increased risk. 1) RLS symptoms often worsen at night and may disturb sleep significantly. 2) Screening for iron deficiency is important in patients with RLS, especially in pregnant women. 3) Conservative management is usually effective in mild cases, particularly during pregnancy. Recent research continues to underscore the role of iron deficiency and dopamine dysfunction in the pathogenesis of RLS. Updated guidelines recommend a careful assessment of iron status and cautious use of dopaminergic agents during pregnancy and lactation.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Q about psp asking about diagnosis",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder characterized by motor dysfunction, postural instability, and vertical gaze palsy. Its diagnosis is primarily clinical but is supported by imaging studies. PSP is a tauopathy, meaning it is associated with abnormal tau protein deposition, leading to neuronal degeneration predominantly in the brainstem, basal ganglia, and frontal lobes. This degeneration underlies the characteristic clinical features of PSP. Patients typically present with early postural instability, frequent falls, and difficulties with vertical gaze, especially downgaze. Cognitive dysfunction and pseudobulbar affect may also be present. These clinical manifestations help differentiate PSP from other parkinsonian disorders. Diagnosis is based on clinical criteria (e.g., the presence of vertical supranuclear gaze palsy) and supported by neuroimaging findings such as midbrain atrophy (the 'hummingbird sign') on MRI. Differential diagnoses include Parkinson\u2019s disease, multiple system atrophy, and corticobasal degeneration, which are differentiated by their distinct clinical and imaging profiles. There is no disease-modifying treatment for PSP. Management is supportive and palliative, including physiotherapy, speech therapy, and careful management of motor symptoms. Trials of dopaminergic therapies are generally less effective in PSP. In the context of pregnancy and lactation, although PSP is primarily a disease of older adults, any symptomatic treatment must consider the safety profile of medications. Although the specific answer options are not provided, the marked answer B is assumed to correlate with a diagnostic criterion typical for PSP (such as vertical gaze palsy or characteristic imaging findings). Thus, based on the available information and common exam paradigms, the marked answer is accepted as correct. 1) Vertical supranuclear gaze palsy is a hallmark of PSP. 2) Early falls and postural instability help differentiate PSP from classic Parkinson\u2019s disease. 3) The 'hummingbird sign' on MRI is a useful imaging correlate for PSP. Emerging research is investigating tau-directed therapies in PSP, though current management remains symptomatic. Latest consensus guidelines emphasize the role of clinical criteria supplemented by neuroimaging in reaching a diagnosis.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "What is the PET finding in CBDG:",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Corticobasal Degeneration (CBD) is a neurodegenerative tauopathy characterized by asymmetric motor and cognitive deficits. PET imaging is valuable in demonstrating metabolic changes in affected brain regions. In CBD, there is asymmetric neuronal degeneration, particularly in the frontoparietal cortex and basal ganglia. This degeneration leads to reduced glucose metabolism in these regions, which is captured on FDG-PET scans. Clinically, patients present with asymmetric limb rigidity, apraxia, and cortical sensory deficits. The asymmetry observed clinically is mirrored by the asymmetric hypometabolism on PET imaging, aiding in the differentiation from other parkinsonian syndromes. FDG-PET is used to demonstrate asymmetric hypometabolic patterns in the affected hemisphere. Differential diagnoses include Progressive Supranuclear Palsy (which typically shows more symmetric midbrain changes) and other atypical parkinsonian disorders. Correlation with clinical findings is critical for accurate diagnosis. There is no curative treatment for CBD; management is primarily supportive. Pharmacologic treatments target parkinsonian symptoms but often have limited efficacy. Physical and occupational therapies are important. In the rare instance of a pregnant or lactating patient (not typical given the age group), treatment would necessitate careful medication selection with a focus on non-pharmacologic interventions and supportive measures. With the options not explicitly provided, the marked answer B is presumed to indicate the classical PET finding in CBD, i.e., asymmetric hypometabolism (commonly in the frontoparietal region and basal ganglia contralateral to the dominant motor symptoms). This is consistent with published literature and imaging criteria for CBD. 1) Asymmetry on FDG-PET is a key imaging signature of CBD. 2) The clinical presentation usually correlates with the side of hypometabolism seen on imaging. 3) Differentiating CBD from other parkinsonian syndromes relies on both clinical and imaging findings. Recent studies reinforce the role of FDG-PET imaging in the early diagnosis of CBD. Biomarkers and advanced imaging techniques continue to evolve, potentially offering earlier diagnostic capabilities and aiding in future therapeutic trials targeting tau pathology.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "a man who presented with abnormal movement (from psychiatry hospital) and being unable to sit still, on exam he is a fidget and move back and forth and keep crossing and uncrossing his legs what is the diagnosis",
    "option_a": "chorea",
    "option_b": "dystonia",
    "option_c": "akathesia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Akathisia is a drug-induced movement disorder characterized by a subjective sense of inner restlessness and an irresistible urge to move. It is most commonly encountered in patients on antipsychotic therapy or other dopamine antagonists. The condition is believed to result from dopamine D2 receptor blockade in the nigrostriatal pathway, leading to an imbalance between dopaminergic and serotonergic/noradrenergic activity. Recent evidence also suggests involvement of other neurotransmitter systems contributing to the motor restlessness. Patients typically present with symptoms of restlessness, an inability to remain still, and observable fidgety movements such as pacing or repeatedly crossing and uncrossing the legs. It is important to differentiate akathisia from anxiety or agitation since the subjective component (restlessness) often accompanies the objective motor signs. The diagnosis is primarily clinical. The differential includes conditions such as tardive dyskinesia (characterized by repetitive, involuntary movements that are not typically described as restlessness), Parkinsonism (bradykinesia rather than restlessness), and restless legs syndrome (which has a distinct circadian pattern and is more common at night). Detailed drug history, especially relating to antipsychotic use, is critical in the evaluation. First-line management includes reducing the causative medication dose if possible, switching to a different antipsychotic with a lower risk for akathisia, and using beta-blockers (e.g., propranolol) or benzodiazepines (e.g., lorazepam) to alleviate symptoms. In pregnancy and lactation, beta-blockers and benzodiazepines should be used with caution; risks versus benefits must be carefully weighed, and close monitoring is essential. Option A (chorea) is incorrect because chorea involves involuntary, flowing, dance-like movements, not the restlessness seen in akathisia. Option B (dystonia) is incorrect as dystonia is the sustained, involuntary muscle contraction leading to abnormal postures. Option C (akathisia) correctly identifies the diagnosis, matching the description of restlessness and fidgety behavior. 1. Akathisia often appears within days to weeks of initiating or increasing the dose of a dopamine antagonist. 2. Patients may describe their discomfort as a \"constant need to move\" which distinguishes it from other movement disorders. 3. Management may require both pharmacologic interventions and medication adjustments. Recent clinical reviews emphasize the importance of early recognition of akathisia to prevent non-compliance with antipsychotic treatment. Updated guidelines support the use of beta-blockers and benzodiazepines as effective treatments, and research is ongoing to elucidate the underlying neurotransmitter imbalances.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "16 years old had dystonia improved with wine and her father has the same, what is the treatment?",
    "option_a": "Clonazepam",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "This case points toward a familial movement disorder with dystonic features that responds to alcohol (wine). Such alcohol responsiveness is a classic clue for myoclonus-dystonia, an autosomal dominant disorder wherein both myoclonic jerks and dystonic posturing may be seen. Myoclonus-dystonia is most commonly associated with mutations in the SGCE gene. The abnormal protein function is thought to lead to dysfunction in basal ganglia circuits and cerebellar pathways, resulting in uncontrolled muscle contractions and jerks. Alcohol temporarily modulates neuronal excitability, which is why symptoms often improve after alcohol intake. Patients often present during adolescence with a combination of dystonia and myoclonus. A positive family history further supports an inherited disorder. The improvement with alcohol is a hallmark; however, the precise mechanism remains under investigation. The diagnosis is clinical, bolstered by a positive family history and characteristic response to alcohol. Differential diagnoses include dopa-responsive dystonia (which typically shows marked improvement with levodopa and has diurnal variation) and other primary dystonias. Genetic testing for SGCE mutations may be considered for definitive diagnosis. First-line treatment is symptomatic. Clonazepam, a benzodiazepine, is effective in reducing both myoclonic jerks and dystonic posturing. Levetiracetam is another option that has shown efficacy. In refractory cases, deep brain stimulation might be considered. In pregnant women and those who are lactating, the use of clonazepam requires careful consideration due to its potential teratogenic risks (Category D in pregnancy) and possible sedation in neonates; risk-benefit analysis and consultation with a specialist are advised. Option A (Clonazepam) is correct as it is widely used to manage symptoms in myoclonus-dystonia. Other options, while not provided, might have included antiepileptics or other benzodiazepines; however, clonazepam remains a well-recognized first-line choice. Its efficacy in managing both the myoclonic and dystonic components of the disorder makes it a reasonable treatment option. 1. Improvement of symptoms with alcohol is a key clinical clue to myoclonus-dystonia. 2. A positive family history supports an autosomal dominant inheritance pattern. 3. Clonazepam is effective but requires caution in populations such as pregnant women. Recent studies have focused on the genetic underpinnings of myoclonus-dystonia and have reinforced the role of SGCE mutations. Clinical trials continue to evaluate the benefits of clonazepam and other agents like levetiracetam, and emerging evidence supports a multidisciplinary approach including possible neuromodulation for refractory cases.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "female pt tailor presented with jerks movements improved with wine her father has same symptoms, Dx:",
    "option_a": "Myoclonus dystonia",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "The presentation of jerky movements (myoclonus) that improve with alcohol, combined with a positive family history, is characteristic of myoclonus-dystonia. This disorder features both myoclonic jerks and dystonic postures and is often inherited in an autosomal dominant manner. Most cases of myoclonus-dystonia are associated with mutations in the SGCE gene. This genetic defect leads to the disruption of normal basal ganglia function, affecting motor control and leading to the characteristic movement abnormalities. The transient improvement with alcohol is thought to be due to its effects on GABAergic neurotransmission. Clinically, patients present in childhood or adolescence with myoclonic jerks, often accompanied by dystonic posturing. The notable improvement with alcohol (such as wine) helps distinguish it from other movement disorders. Familial occurrence further strengthens the diagnosis. The diagnosis is primarily clinical. Differential diagnoses include essential tremor, other forms of primary dystonia, and dopa-responsive dystonia. Genetic testing for SGCE mutations can confirm the diagnosis. Electrophysiological studies may demonstrate the characteristic myoclonic activity. Treatment is symptomatic. Clonazepam is commonly employed as a first-line agent to reduce both myoclonic and dystonic movements. Alternative therapies such as levetiracetam have been reported to be effective. In refractory cases, deep brain stimulation (DBS) is an option. In the context of pregnancy and lactation, the use of clonazepam requires heightened caution due to potential teratogenic effects and neonatal sedation; careful risk-benefit analysis is necessary. Option A (Myoclonus dystonia) directly corresponds to the clinical picture provided. The familial component, the improvement with alcohol, and the presence of jerks are all consistent with this diagnosis, making it the best choice among the options. 1. Alcohol responsiveness is a unique and important clinical clue in diagnosing myoclonus-dystonia. 2. A strong family history supports an autosomal dominant pattern of inheritance. 3. Treatment centers on symptom control with medications such as clonazepam. Recent research has validated the role of SGCE mutations in myoclonus-dystonia and has explored various therapeutic options including clonazepam and levetiracetam. Newer treatment modalities, such as DBS, are under investigation for patients who do not respond adequately to medical management.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "typical orthostatic tremor, what is the treatment:",
    "option_a": "Clonazepam",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Orthostatic tremor is characterized by a rapid, high-frequency tremor that occurs primarily in the legs when standing. Patients often describe a feeling of unsteadiness or shakiness that rapidly improves when sitting or walking. The tremor is thought to originate from abnormal oscillatory activity in a cerebellothalamocortical network. Electromyography typically reveals a tremor frequency between 13 and 18 Hz. The precise pathogenesis remains under investigation, but it is distinct from other tremor syndromes due to its unique frequency and clinical presentation. Patients with orthostatic tremor usually complain of a feeling of instability when standing for prolonged periods. The high-frequency tremor is typically not visible but can be confirmed by EMG. The condition may significantly impair daily activities by limiting the duration a patient can stand or ambulate without support. Diagnosis is confirmed with electromyography (EMG), which identifies the characteristic high-frequency tremor. Differential diagnoses include essential tremor (which is typically lower in frequency and not exclusively related to posture) and other forms of postural tremor. A detailed history and physical exam are critical in distinguishing these entities. First-line treatment for orthostatic tremor is clonazepam, which has been shown to reduce tremor amplitude and improve symptoms. Alternative treatments include gabapentin and primidone. In pregnancy and lactation, use of clonazepam requires careful consideration due to its potential teratogenicity and risks of neonatal sedation; therefore, therapy should be individualized and closely monitored, with non-pharmacologic strategies considered when possible. Option A (Clonazepam) is correct because it has well-documented efficacy in reducing orthostatic tremor symptoms. Other potential treatment options, which are not listed here, may include gabapentin, but clonazepam remains a mainstay in clinical practice, particularly in patients with significant symptoms. 1. Orthostatic tremor should always be confirmed with EMG due to its unique high-frequency characteristics. 2. Symptoms are specifically triggered by standing and rapidly improve with sitting or walking. 3. Clonazepam is the best-supported initial therapy despite potential side effects, especially in vulnerable populations. Recent literature supports clonazepam as a first-line agent, with numerous case series and small studies demonstrating its efficacy. Research is also exploring alternative medications and combination therapy approaches, and there is ongoing investigation into the underlying neural circuitry involved in orthostatic tremor.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Same scenario, what is next?",
    "option_a": "Start levodopa ?",
    "option_b": ", which is assumed to represent an alternative first",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to hallmark motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability. In early-stage PD, especially in younger patients, treatment decisions are individualized to balance symptomatic benefit with the potential long\u2010term side effects of medications. PD involves degeneration of dopamine\u2011producing neurons with resultant depletion of striatal dopamine. The pathological process is associated with the formation of Lewy bodies (aggregates of alpha-synuclein) and involves multiple mechanisms including mitochondrial dysfunction, oxidative stress, and protein misfolding. This underlies the clinical manifestations of the disease. Patients typically present with unilateral or asymmetrical motor symptoms initially, progressing to bilateral involvement as the disease advances. In younger patients, the strategy is often to delay the introduction of levodopa to reduce the risk of motor complications such as dyskinesia over time. The scenario alludes to an early treatment decision where starting levodopa (option A) may not be the optimal choice, and an alternative (option B) is preferred. Diagnosis is mostly clinical, supported by a history of progressive motor symptoms and a positive response to dopaminergic treatment. Differential diagnoses include drug\u2010induced parkinsonism, atypical parkinsonian syndromes (such as multiple system atrophy or progressive supranuclear palsy), and essential tremor. Ancillary testing like a DaTscan can be useful if the diagnosis is ambiguous. First-line management in early PD, especially in younger individuals, often favors a trial of dopamine agonists (or other non-levodopa options) to achieve symptomatic control while minimizing long-term levodopa complications. If symptoms worsen or in older patients, levodopa remains the gold standard. In pregnant or lactating patients, levodopa is generally considered relatively safe, but therapy should be individualized with close monitoring and weighing risks versus benefits. Option A (Start levodopa) might be more appropriate for older patients or in advanced disease, but in early PD in a younger patient, it may lead to earlier onset of levodopa-induced dyskinesia. Option B, which is assumed to represent an alternative first-line approach (such as initiating a dopamine agonist), is therefore the correct choice. Options C and D are not specified and do not alter this reasoning. 1. Younger PD patients benefit from delaying levodopa therapy to postpone motor complications. 2. Dopamine agonists are commonly used as first-line treatment in early PD for younger individuals. 3. The diagnosis of PD remains primarily clinical, with supportive imaging used in unclear cases. Recent guidelines and clinical studies emphasize individualized treatment in PD with a focus on quality of life. There is ongoing research into neuroprotective therapies and optimizing the timing of levodopa introduction, supporting the approach of using alternative agents in early disease management.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]